Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Revefenacin

A long-acting muscarinic antagonist (LAMA) bronchodilator, approved in the United States in 2018 for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It was the first once-daily nebulised bronchodilator for COPD: it is inhaled with a standard jet nebuliser rather than a handheld inhaler.

RevefenacinGo to the active ingredient →
RevefenacinActive ingredientRevefenacinCat. No. P-R046-001CAS 864750-70-9

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.